Peginterferon Alpha-2a
PreclinicalSmall molecule
Johnson & JohnsonPeginterferon Alpha-2a is one of 15 small molecule programs targeting Portal Hypertension. It is currently in Preclinical.
1
Indications
12
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Portal Hypertension
#DrugCompanyPhaseTrials
1Coreg
Akero TherapeuticsApproved
Zocor
OOrganon and Co
Approved
Nexavar
BayerApproved
Sandostatin
Sun PharmaApproved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Glucophage
EMD SeronoPhase 2
Cadonilimab
SShanghai Pharmaceuticals Holding Co., Ltd
Phase 2
Donafenib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Alverine
SShanghai Changzheng Hospital
Phase 3
HEPCLUDEX
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis6 trials
Show 3 more trials
Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues
Unknown status·—·Phase 4·NCT02362490·200 enrolled
Pegylated Interferon to Treat Chronic Hepatitis D
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00023322·13 enrolled
Hepatitis C3 trials
Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00122616·52 enrolled
Randomized1 trial
Portal Hypertension1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peginterferon Alpha-2a. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company